Business News

    Radiopharm Theranostics (ASX:RAD) to raise $10M for clinical trial advancements

    Article Image

    Radiopharm Theranostics plans to raise approximately $10 million through a non-renounceable entitlement offer, with a proposed offer price of 7 Australian cents per new share.

    The offer allows eligible shareholders to subscribe to one new ordinary share for every 2.35 existing shares.

    The company aims to utilise the funds for advancing multiple clinical trials, bolstering working capital, and covering the costs of the offer.

    The entitlement offer is set to open on Nov. 8 and close on Nov. 24. A top-up facility will be available for eligible shareholders who fully take up their entitlements.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa